Varenicline Versus Cytisine for Smoking Cessation in Primary Care Setting
Status:
Recruiting
Trial end date:
2021-10-01
Target enrollment:
Participant gender:
Summary
The overall goals of this study are to 1) assess awareness of interest in the use of
pharmacotherapy for smoking cessation in Croatia and Slovenia, countries in Central Europe
with very high smoking prevalence, and 2) investigate whether cytisine is at least as
feasible and effective as varenicline in helping smokers to quit in a real-life setting:
family medicine practices in Croatia and Slovenia. The investigators propose to survey
patients from 40 primary care practices (20 in Croatia and 20 in Slovenia) to assess desire
to quit smoking and awareness and interest in pharmacotherapy. Additionally, 380 patients
with interest in quitting smoking will be randomly assigned to use varenicline or cytisine to
help quit smoking.
The investigators hypothesize that cytisine is at least as feasible and effective as
varenicline in helping smokers from primary care practices in Croatia and Slovenia to quit
smoking.
Phase:
Phase 3
Details
Lead Sponsor:
University of Zagreb
Collaborators:
Harvard Medical School Harvard Medical School (HMS and HSDM) Massachusetts General Hospital University of Ljubljana School of Medicine, Slovenia University of Zagreb School of Medicine